RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection

Launched by E-DA HOSPITAL · Jun 8, 2017

Keywords

ClinConnect Summary

This clinical trial is investigating whether a treatment called radiofrequency ablation (RFA) can help prevent the recurrence of esophageal cancer in patients who have already undergone a procedure to remove early-stage tumors. After complete removal of these tumors, many patients are at risk of developing new cancerous lesions, especially those with a specific pattern of staining in the esophagus, known as "speckled" lugol staining. The researchers believe that by using RFA on these areas, they may be able to reduce the chances of new tumors forming.

To be eligible for this trial, participants need to be adults who have been diagnosed with early-stage esophageal squamous cell neoplasia and have undergone a specific treatment called endoscopic submucosal dissection. They must also show the "speckled" pattern in their esophagus. Participants in the trial can expect to receive close monitoring and care, and they will be contributing to important research that could help improve treatment options for future patients facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults with early stage ESCNs (squamous high grade dysplasia, carcinoma in situ, or T1N0M0 SCC) who were treated by endoscopic submucosal dissection.
• • Lugol staining showed "speckled" (\>10 small lugol-unstained lesions) pattern of background mucosa.
• Exclusion Criteria:
• • Having a history of incomplete endoscopic treatment, or complications during/after treatment (perforation, stricture).
• • Having history of systemic chemotherapy or radiation therapy for esophagus or post esophagectomy.
• • Life expectancy \<2 yr.
• • Decompensated cirrhosis (Child score B, C).
• • Having large esophageal varices.
• • Poor performance status (ECOG\>2).